$2.800
-0.124 (-4.44%)收盘时
OVID 资讯
OVID 事件
Ovid Reports Q2 Revenue of $733,000
Reports Q2 revenue $733,000 vs. $6.27M last year. "Ovid is focused on the execution of multiple near-term clinical, proof-of-concept studies across our differentiated pipeline," said Meg Alexander, President and Chief Executive Officer. "Our team is well positioned to realize the potential of KCC2 direct activation and GABA aminotransferase inhibition for many intractable disorders of the brain. Additionally, through the recent transaction with Perceptive Advisors and Takeda, Ovid has the potential to realize value from our interests in soticlestat, which may provide future capital to Ovid and most importantly, advance a meaningful therapy to epilepsy patients who can benefit."
Ovid Therapeutics Announces New Executive Appointments
Ovid Therapeutics announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to spearhead business and corporate development functions as well as strategic partnerships. Charles Carter was promoted to CFO and will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives. Most recently, Norrett served as chief business officer at Soleno Therapeutics.
Meg Alexander: Company Progressing Well, Well Capitalized into 2029
"Our first quarter reflected focused execution and continued progress across our pipeline of potentially transformative small molecule medicines for intractable brain conditions," stated Meg Alexander, President and Chief Executive Officer. "Our development programs remain on track, our clinical organization has expanded, and we expect to be well capitalized into 2029, positioning us for multiple anticipated proof-of-concept and proof-of-signal readouts. We are especially pleased to have initiated Phase 1 dosing this month for our oral KCC2 direct activator, OV4071, alongside the expansion of OV329's development programs, as we advance therapies targeting mechanisms central to excitatory/inhibitory balance in the brain."
Ovid Therapeutics Files to Sell 29.86M Shares of Common Stock
Ovid Therapeutics files to sell 29.86M shares of common stock for holders
Major Averages Decline Amid Middle East Conflict
The major averages closed lower following a series of volatile sessions where markets have swung sharply based on headlines tied to the Middle East conflict and energy supply disruptions. Reports of fresh attacks on Iranian energy infrastructure caused intraday swings in both oil and equities once again on Wednesday.Traders also reacted to news from the U.S. Federal Reserve, which maintained the federal funds rate, saying that economic uncertainty "remains elevated" given developments in the Middle East. Of note, the Fed said the median projection for the funds rate by the end of 2026 remains at 3.4%, indicating most officials at the central bank still expect at least one quarter-point cut to interest rates this year.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:General Millsreportedand reiterated its FY26 outlookMacy'sreportedand provided guidance for FY26Lululemonreportedand provided its outlook for Q1 and FY26Compassdismissedagainst ZillowThe Federal Reserve left the federal funds rate2. WALL STREET CALLS:CitiConstellationto Buy on better beer trendsTruistBlockto Buy following 40% reduction in forceTrade Deskat Rosenblatt and Stifel amid pressures from agenciesRBC CapitalStarbucksto Sector Perform on balanced risk/rewardCF Industriesto Underperform at Mizuho3. AROUND THE WEB:Kraft Heinzand Unileverdiscussed a potential food merger, FT reportsFox Corp.and Kalshi are in talks on a partnership deal, Front Office Sports reportsMicrosoftis weighing legal action against Amazonand OpenAI over a $50B deal that may breach its exclusive cloud partnership with OpenAI, FT reportsThe U.S. government confirmed that Teslais the customer behind LG Energy Solution's $4.3B LFP battery supply deal, ending speculation since the contract was disclosed last July, Electrek saysNebiusintends to raise about $3.75B in convertible debt to use for its data center expansion and to purchase customized chips, and plans to offer the notes in two series, at $2B due in 2031 and $1.75B in 2033, Bloomberg says4. MOVERS:Ovid Therapeuticsgains after, Phase 1 clearance for OV4071, and results for Q4Nextnavand Energy VaultincreasesnVent Electrichigher in New York after updating itsGeminilower after Citithe stock to SellSailPointfalls afterand providing guidance for FY275. EARNINGS/GUIDANCE:Williams-Sonomaand provided guidance for FY26Spire Globaland provided guidance for Q1 and FY26Jabiland raised its guidance for FY26Weibo, with EPS missing consensusOrbit International, with EPS and revenue lower year-over-yearINDEXES:The Dow fell 768.11, or 1.63%, to 46,225.15, the Nasdaq lost 327.11, or 1.46%, to 22,152.42, and the S&P 500 declined 91.39, or 1.36%, to 6,624.70.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。